JCOGの基本情報 > 研究実績 > 泌尿器科腫瘍グループ

JCOGの基本情報泌尿器科腫瘍グループ

更新日：2010年8月31日

  1. 論文
    1. 委員会承認の治療研究

      なし

    2. グループ代表者管理の治療研究
      • A Yokomizo, K Tobisu, H Kawamoto, et al.: Randomized Controlled Trial to Evaluate Radiation plus Endocrine Therapy or Endocrine Therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 35: 34-36, 2005.
      • Y Matsui, H Nishiyama, O Ogawa, et al.: The current status of perioperative chemotherapy for invasive bladder cancer : a　multiinstitutional retrospective study in Japan. Int J Clin Oncol, 10: 133-138, 2005.
      • X Wu, Y Kakehi, et al.: Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol, 174: 2138-2143, 2005.
      • K Kawamoto, H Enokida, M Nakagawa, et al.: p16 (INK4a) and p14 (ARF) methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339: 790-796, 2006.
      • H Kitamura, T Tsukamoto. Early bladder cancer: concept, diagnosis,and management. Int J Clin Oncol, 11: 28-37, 2006.
      • I Honma, N Masumori, T Tsukamoto, et al.: Removal of more lymph nodes may provide a better outcome as well as more accurate pathology in patients with bladder cancer-An analysis of the role of pelvic lymph node dissection, Urology. 68:543-548, 2006.
      • I Honma, N Masumori N, Sato E, et al.: Removal of lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer-analysis of role of pelvic lymph node dissection. Urology.68: 543-548,2006.
      • A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen(PSA) level, pT and Gieason score as predictors of PSA recurrence after radical prostatectomy; a multi-institution outcome study in Japan. BJU Int. 98:549-553,2006.
      • T Shindo, N Masumori, F Fukuta, et al.: Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease? Jpn J Clin Oncol. 40:153-156, 2010.
    3. 附随研究等

      A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int. 98:549-553, 2006.

      塚本泰司、前田俊浩、福多史昌:筋層浸潤膀胱癌におけるneoadjuvant chemotherapyの意義.泌尿器外科.20:1137-1145, 2007.

      Y Kakehi, T Kamoto, T Shiraishi, et al,：Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1c N0 M0 Prostate Cancer.Jpn J Clin Oncol 38 (2):122-128,2008.

    4. 総説・解説

      S Naito: Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Jpn. J. Clin. Oncol. 35:365-374, 2005.

  2. 主な学会発表
    1. 委員会承認の治療研究

      横溝 晃、古賀寛史、此元竜雄、他：早期前立腺がんにおける根治術後の再発に関するoutcome study. 第41回日本癌治療学会総会. 2000年.

    2. グループ代表者管理の治療研究
      • S Naito: Treatment of Patients with PSA Recurrence after Radical Prostatectomy. The 18th International Symposium of Foundation for Promotion of Cancer Research, 2005.
      • Y Kakehi, T Kamoto, T Shraisi, et al.: PSA doubling time assessment based upon 4 consecutive measurements for 6 months: Is it a realistic strategy to spare over-treatment for patients with stage T1c prostate cancer presenting favorable biopsy features? Annual American Urological Association Meeting, 2006.
      • 横溝晃、古賀寛史、鳶巣賢一、他：日本の早期前立腺がん根治手術後の再発に関するアウトカム研究 第93回日本泌尿器科学会総会.　2005年4月.
    3. 附随研究等

      なし

    4. 総説・解説

      なし

トップへ戻る